Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Tctex2 CRISPR/Cas9 KO Plasmid (m): sc-423317
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Tctex2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Tctex2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Tctex2 Antibody (H-5): sc-74541
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tctex2 CRISPR/Cas9 KO Plasmid (m) | sc-423317 | 20 µg | $397.00 |
Overview
Tcte3 encodes Tctex2, a dynein light chain–associated protein implicated in microtubule-based transport processes that support cellular polarization and motility. In mouse, Tctex2 is most strongly linked to cilia and flagella function, where dynein-driven movement and cargo trafficking are essential for axonemal dynamics and sperm motility. Disruption of dynein accessory components can perturb ciliogenesis, intraflagellar transport, and centrosome-related organization, creating measurable effects on cell signaling and developmental patterning. Consequently, Tcte3/Tctex2 is relevant to research on cilia-associated phenotypes, male infertility models, and mechanisms connecting cytoskeletal transport to tissue homeostasis.
Tctex2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Tcte3 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Tcte3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Tcte3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Tctex2 protein expression.
This CRISPR knockout system enables efficient generation of Tcte3-deficient cell models for investigation of Tctex2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Tcte3 exon(s) critical for Tctex2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Tcte3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Tctex2 CRISPR/Cas9 KO Plasmid (m) and Tctex2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Tcte3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Tctex2 HDR Plasmid (m) and Tctex2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Tcte3 homology arms to support homology-directed repair at defined Tcte3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.